FASN and prostate carcinoma: In this type of cancer, the use of alpinumisoflavone, could disrupt intracellular FAs, cholesterols, and LD contents in prostate cancer cells through an inhibition of FASN and 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) [78].